Martin Buckland was appointed Chief Corporate Officer of Astex Pharmaceuticals, Inc. in January 2015. He joined Astex Therapeutics Limited as Chief Business Officer in September 2004 and served as a member of the Board of Directors from July 2008 through the merger with SuperGen Inc. to create Astex Pharmaceuticals, Inc., in July 2011. He has more than 30 years of commercial, corporate and business development experience in the pharmaceutical industry and joined Astex from Elan Pharmaceuticals, where he previously held the position of Vice President of Global Business Development. His prior experience includes a variety of business development and commercial management roles with Quintiles, Xenova and Celltech. Dr. Buckland was awarded the 2009 AstraZeneca Business Development Professional of the Year Award by the Pharmaceutical Licensing Group. He has a BA in Chemistry and a DPhil from the University of Oxford, UK, and an MBA from the Open Business School.